Guardant Health Inc (GH)

Nov 11, 2026

Guardant Health has expanded its Guardant360 Liquid blood test with five new epigenomic applications designed to improve breast and lung cancer treatment selection. These additions use the company's InfinityAI platform to combine genomic and epigenomic signals, aiming to inform therapy choices when conventional mutation markers are insufficient. The company reported $231.3 million in third-quarter revenue, with oncology test volume up 58 percent year-over-year.

Nov 10, 2026

Guardant Health (GH) stock rose 5.2% on November 9, 2026, outperforming the S&P 500, despite no direct company announcement. The rise followed the company's third-quarter report on November 5, where it announced a 36% revenue growth, a 180% increase in Shield revenue, and raised its full-year 2026 revenue outlook. The company also adjusted its free cash flow burn outlook due to a temporary delay in CMS claims processing for a new test.

Nov 5, 2026

Guardant Health (GH) reported a Q3 loss of $0.29 per share, matching the Zacks Consensus Estimate, and surpassed revenue estimates with $360.98 million. The company has topped consensus revenue estimates four times in the last four quarters, with its shares gaining 65.1% year-to-date. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.

Nov 5, 2026

Guardant Health (NASDAQ: GH) surpassed Wall Street's revenue and EPS expectations in Q3 2026, with revenue increasing 36.1% year-on-year to $361 million and a non-GAAP loss of $0.29 per share. Despite these positive results and an increased full-year revenue guidance, the company's stock declined by 10.2% immediately after the announcement. This suggests that while the financial performance was strong, the market may have anticipated even more significant upside.

Nov 1, 2026

This article analyzes Guardant Health Inc. (NYSE: GH), highlighting a strong sentiment across all horizons and an exceptional 57.2:1 risk-reward setup targeting a 16.4% gain versus 0.3% risk. It outlines three distinct AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with a multi-timeframe signal analysis.

Oct 29, 2026

Guardant Health (GH) is anticipated to surpass earnings estimates for the quarter ending September 2026, driven by an expected year-over-year increase in revenues and earnings. The company's Zacks Earnings ESP of +4.76% combined with a Zacks Rank of #3 suggests a high probability of an earnings beat, according to Zacks Investment Research. Investors are advised to consider other factors alongside these indicators.